Financial & Tax Architects LLC Acquires 1,525 Shares of Sanofi (NASDAQ:SNY)

Financial & Tax Architects LLC boosted its holdings in Sanofi (NASDAQ:SNY) by 14.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 11,824 shares of the company’s stock after acquiring an additional 1,525 shares during the period. Financial & Tax Architects LLC’s holdings in Sanofi were worth $570,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in SNY. Charles Schwab Investment Management Inc. boosted its stake in Sanofi by 31.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 139,505 shares of the company’s stock valued at $8,040,000 after buying an additional 33,105 shares in the last quarter. Geode Capital Management LLC boosted its stake in Sanofi by 7.1% in the third quarter. Geode Capital Management LLC now owns 254,738 shares of the company’s stock valued at $14,681,000 after buying an additional 16,780 shares in the last quarter. GFS Advisors LLC boosted its stake in Sanofi by 1,017.9% in the third quarter. GFS Advisors LLC now owns 12,800 shares of the company’s stock valued at $738,000 after buying an additional 11,655 shares in the last quarter. Legacy Capital Wealth Partners LLC boosted its stake in Sanofi by 114.2% in the third quarter. Legacy Capital Wealth Partners LLC now owns 24,274 shares of the company’s stock valued at $1,399,000 after buying an additional 12,942 shares in the last quarter. Finally, Icon Wealth Advisors LLC boosted its stake in Sanofi by 7,954.4% in the third quarter. Icon Wealth Advisors LLC now owns 292,779 shares of the company’s stock valued at $16,873,000 after buying an additional 289,144 shares in the last quarter. Institutional investors own 14.04% of the company’s stock.

Sanofi Price Performance

Shares of SNY stock remained flat at $50.74 during mid-day trading on Friday. The stock had a trading volume of 2,426,236 shares, compared to its average volume of 2,173,288. The business has a fifty day moving average price of $48.46 and a two-hundred day moving average price of $52.09. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The stock has a market capitalization of $128.77 billion, a P/E ratio of 25.89, a price-to-earnings-growth ratio of 1.17 and a beta of 0.57. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a return on equity of 27.45% and a net margin of 9.96%. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same period last year, the company earned $2.55 earnings per share. The firm’s revenue was up 12.3% compared to the same quarter last year. On average, equities research analysts anticipate that Sanofi will post 3.94 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Two investment analysts have rated the stock with a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.